Login to Your Account



Biogen, Elan Again Put Fate Of Tysabri Into FDA's Hands

By Aaron Lorenzo


Wednesday, September 28, 2005
The FDA now finds itself in an unenviable position, after receiving an application to clear Tysabri (natalizumab) again, seven months after the multiple sclerosis product was pulled from the market following its links to two fatalities, despite showing clinical efficacy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription